AstraZeneca Pharma India share price
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
AstraZeneca Pharma India Limited · Formerly Astra IDL · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1982 on BSE, May 2001 on NSE
Last close ₹6,073.00up ₹21.50 (0.36%)BSE ₹6,073.10
Share price at the NSE close on 27 Oct 2026. Previous close ₹6,051.50.
27 Oct: open ₹5,992.00, high ₹6,104.00, low ₹5,990.00
52-week range of traded prices to 27 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,183 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 89.51
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 17.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,04453.7% delivered
Results
Standalone; ₹ crore.AstraZeneca Pharma India quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +31.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −7.5%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹683 Crup 18.01%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹38 Crdown 15.49%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 5.6%
Revenue by quarter
Peak revenue ₹683 Cr, quarter to Jun 2026; lowest ₹408 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 |
| Net profit | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 |
| Net margin | 9.4% | 7.0% | 12.1% | 10.6% | 9.7% | 5.3% | 7.8% | 5.6% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2,276 Crup 32.59%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹188 Crup 62.02%
- Net margin
- 8.2%
Revenue by year
Peak revenue ₹2,276 Cr, year to Mar 2026; lowest ₹540 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 540 | 572 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 |
| Net profit | 24 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 188 |
| Net margin | 4.5% | 4.5% | 7.5% | 8.7% | 11.5% | 7.6% | 9.9% | 12.5% | 6.7% | 8.2% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Healthcare, which carries all its revenue.
Valuation
Today, against the company's own history.AstraZeneca Pharma India PE ratio and valuation
Price to earnings
At or below today's level on 25% of 2,478 trading days over the last 10 years.
LowestHighest
Its median105.38Industry median28.32
Price to book
At or below today's level on 33% of 1,964 trading days since Nov 2018.
LowestHighest
Its median20.36Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 99% of 2,454 trading days over the last 10 years.
LowestHighest
Its median0.06%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −9.3% | +62.0% | −44.3% | 0.5% |
| 3 years | +34.1% | +23.6% | +8.1% | 0.4% |
| 5 years | +21.3% | +15.0% | +5.1% | 0.4% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 and 3 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2023 and Mar 2025.
Mutual fund holdings
29 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 3 of the 11 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 29 funds holding AstraZeneca Pharma India
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 8
- CutCut. Funds that held fewer shares than at the end of the month before.
- 3
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 17
| Fund | |||
|---|---|---|---|
 Nippon India Small Cap FundNippon India Mutual Fund | 6,61,875 | 0.51% | ₹409.4 Cr |
 ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 2,04,986 | 1.85% | ₹126.8 Cr |
 Bandhan Large & Mid Cap FundBandhan Mutual Fund | 1,70,548 | 0.51% | ₹105.5 Cr |
| Bandhan Innovation FundBandhan Mutual Fund | 1,20,087 | 2.41% | ₹74.3 Cr |
| ICICI Prudential Quality FundICICI Prudential Mutual Fund | 81,005 | 2.50% | ₹50.1 Cr |
| ICICI Prudential Multi Cap FundICICI Prudential Mutual Fund | 78,271 | 0.26% | ₹48.4 Cr |
| ICICI Prudential Innovation FundICICI Prudential Mutual Fund | 76,227 | 0.62% | ₹47.2 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 62,568 | 0.42% | ₹38.7 Cr |
| ICICI Prudential Manufacturing FundICICI Prudential Mutual Fund | 42,476 | 0.38% | ₹26.3 Cr |
| ICICI Prudential Small Cap FundICICI Prudential Mutual Fund | 33,970 | 0.21% | ₹21.0 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
AstraZeneca Pharma India competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to AstraZeneca Pharma India in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Eris LifesciencesERIS | 16,626 | 23.50 | 4.01 | +11.1% | +70.2% | 19.6% | 13.4% | 0.60% |
 Alivus Life SciencesALIVUS | 16,496 | 27.35 | 4.95 | +7.9% | +21.7% | 19.6% | 22.7% | 0.37% |
 Natco PharmaNATCOPHARM | 15,587 | 13.62 | – | −20.7% | −32.6% | 13.6% | 8.6% | 0.57% |
 Jubilant PharmovaJUBLPHARMA | 15,288 | 43.42 | 2.16 | +16.3% | −23.5% | 5.3% | 7.3% | 0.52% |
 Alembic PharmaceuticalsAPLLTD | 15,074 | 21.81 | 2.66 | +14.1% | +14.6% | 12.7% | 11.8% | 1.56% |
 Concord BiotechCONCORDBIO | 14,388 | 50.94 | 6.93 | +4.0% | −12.8% | 14.5% | 15.9% | 0.55% |
 Marksans PharmaMARKSANS | 13,599 | 26.32 | 4.50 | – | – | 17.1% | 19.9% | 0.30% |
 CORONA RemediesCORONA | 13,162 | 66.13 | 17.62 | – | – | 26.6% | 30.9% | 0.46% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.AstraZeneca Pharma India dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹36.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 31 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹36.00 |
| 18 Jul 2025 | Final | ₹32.00 |
| 5 Jul 2024 | Final | ₹24.00 |
| 14 Jul 2023 | Final | ₹16.00 |
| 7 Jul 2022 | Final | ₹8.00 |
| 18 Aug 2021 | Interim | ₹2.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.AstraZeneca Pharma India announcements
Oct 2026
16 Oct · Rating
Sep 2026
18 Sep · Legal
15 Sep · Management
15 Sep
AstraZeneca Pharma India share price by year
Each calendar year to 2025.AstraZeneca Pharma India share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 9,029.00 | +23.6% | 10,509.50 | 6,698.65 |
| 2024 | 7,305.15 | +32.2% | 7,970.05 | 4,928.05 |
| 2023 | 5,526.60 | +67.6% | 5,644.60 | 3,135.85 |
| 2022 | 3,297.15 | +6.4% | 3,561.35 | 2,460.65 |
| 2021 | 3,098.25 | −32.9% | 4,665.95 | 2,981.05 |
| 2020 | 4,619.20 | +76.5% | 4,642.30 | 1,903.40 |
| 2019 | 2,616.60 | +80.3% | 2,875.20 | 1,415.55 |
| 2018 | 1,451.60 | +24.4% | 1,892.55 | 927.55 |
| 2017 | 1,167.15 | +26.0% | 1,221.40 | 885.55 |
| 2016 | 926.30 | −25.8% | 1,280.20 | 916.95 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 6,000.00 | 6,068.00 | 5,888.00 | 6,051.50 | 6,005.64 | 10,051 | 57.1% |
| 23 Oct 2026 | 6,060.00 | 6,071.50 | 5,850.50 | 5,988.50 | 5,973.36 | 7,118 | 47.8% |
| 22 Oct 2026 | 6,051.00 | 6,129.50 | 5,987.50 | 6,101.00 | 6,074.38 | 4,137 | 47.9% |
| 21 Oct 2026 | 6,023.00 | 6,143.50 | 5,988.50 | 6,079.50 | 6,080.57 | 8,103 | 49.8% |
| 19 Oct 2026 | 5,960.00 | 6,075.00 | 5,850.00 | 6,039.50 | 5,971.85 | 13,651 | 57.0% |
| 16 Oct 2026 | 5,985.50 | 6,009.00 | 5,843.50 | 5,970.50 | 5,943.07 | 10,012 | 61.4% |
| 15 Oct 2026 | 5,930.00 | 6,006.00 | 5,872.50 | 5,937.00 | 5,963.01 | 12,446 | 58.9% |
| 14 Oct 2026 | 5,900.00 | 5,960.00 | 5,835.00 | 5,950.50 | 5,899.28 | 12,179 | 71.2% |
| 13 Oct 2026 | 5,919.00 | 5,926.00 | 5,790.50 | 5,877.50 | 5,853.60 | 43,240 | 84.1% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- ASTRAZEN
- BSE code
- 506820
- ISIN
- INE203A01020
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- ASTRAIDL
- Website
- www.astrazenecaindia.com
- CIN
- L24231KA1979PLC003563
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1979
- Registered office
- Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bengaluru 560045, Karnataka
- Share registrar
- Integrated Registry Management Services Pvt. Ltd.
- Keeps the register of shareholders and handles transfers and dividend payments